Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilotumumab in advanced renal cell carcinoma
NCT00422019Phase 2Completed
- Sponsor
- Amgen
- Start
- Jan 2007
- Primary completion
- Mar 2009
01
Overview
A Phase 2 trial of rilotumumab in renal cell carcinoma (RCC), sponsored by Amgen. Started Jan 2007; status: completed.
02
Drugs
rilotumumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00422019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00422019.